December 10, 2019
Chief Medical Officer at Amylyx Pharmaceuticals gives a closer look at how far they have come in their recently expanded phase 2 clinical trial, supported in part by the ADDF, which is studying a combination approach to treating people with Alzheimer’s disease.
November 22, 2019
The Bluefield Project to Cure FTD Receives $1.2 Million Award from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator
October 17, 2019
The Alzheimer’s Drug Discovery Foundation (ADDF) announced a partnership with Shionogi & Co., Ltd. and Janssen Pharmaceuticals, Inc. as part of its Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias.
October 15, 2019
These recent investments reflect the ADDF's commitment to advancing tools for early detection, with an emphasis on exploring the different pathologies associated with aging.
May 30, 2019
The first four awards from the first request for proposals total up to approximately $3.5 million.
May 10, 2019
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
April 2, 2019
The ADDF's Diagnostics Accelerator is seeking to fund the development of digital tools to capture quantifiable biomarkers.
March 21, 2019
Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.
January 14, 2019
In 2018 we have seen increased investments in Alzheimer's biomarkers and increased interest in prevention.
November 13, 2018
At the ADDF's Ninth Annual Fall Symposium, Richard S. Isaacson, Michelle M. Mielke, and Mark A. Mintun discussed Alzheimer's biomarkers and prevention.